Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial (Q27851852)

17

Keith Flaherty

0 references

Jeffrey R Infante

1

Jeffrey R Infante

0 references

Vijay G R Peddareddigari

11

Vijay G R Peddareddigari

0 references

Leslie A Fecher

2

Leslie A Fecher

0 references

Douglas J DeMarini

7

Douglas J DeMarini

0 references

Howard A Burris

18

Howard A Burris

0 references

Ngocdiep T Le

12

Ngocdiep T Le

0 references

author name string

Gerald S Falchook

3

0 references

Sujatha Nallapareddy

4

0 references

Michael S Gordon

5

0 references

Carlos Becerra

6

0 references

Donna S Cox

8

0 references

Yanmei Xu

9

0 references

Shannon R Morris

10

0 references

Lowell Hart

13

0 references

Johanna C Bendell

14

0 references

Gail Eckhardt

15

0 references

Wells A Messersmith

Lancet Oncology Commission

19

0 references

language of work or name

1 reference

August 2012

0 references

published in

0 references

volume

13

0 references

issue

8

0 references

page(s)

773-81

0 references

cites work

Development of anticancer drugs targeting the MAP kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

A synthetic inhibitor of the mitogen-activated protein kinase cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970270-X

7 January 2021

10.1016/S1470-2045(12)70270-X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

549078

549078

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference